A Phase Ia/Ib Study Exploring The Synthetic Lethality Of The Orally Administered Novel Btk Inhibitor, Dtrmwxhs-12 (Dtrm-12), In Combination With Everolimus And Pomalidomide In Patients With Relapsed/Refractory Cll, Dlbcl Or Other B-Cell Lymphomas
BLOOD(2019)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要